17 June 2022
Neurologist Bas Bloem, MD, PhD, FRCPE of Radboud University Medical Center receives this year’s Stevin Prize of the Dutch Research Council (NWO). The Stevin Award is the highest distinction in science for a researcher in the Netherlands who has achieved particular success in the area of knowledge utilization for society. Prof. Bloem is the recipient of this award for the social impact of his research into this common and debilitating disorder.
20 May 2022
The Journal of Parkinson’s Disease is pleased to announce the appointment of new co-Editor-in-Chief, Lorraine V. Kalia, MD, PhD, FRCPC. Dr. Kalia joins co-Editor-in-Chief Bas Bloem, MD, PhD, FRCPE, and an eminent international editorial board, who are dedicated to the continuing success of the world’s leading journal in Parkinson’s research.
10 May 2022
Although there is a growing trend to involve patients in clinical research, specific guiding principles for engaging individuals with Parkinson’s disease have not been established. The authors of this Call to Action emphasize the value of incorporating patient perspectives in clinical Parkinson’s disease studies and recommend how to include patient researchers effectively.
14 April 2022
We share the news that Patrik Brundin, MD, PhD has decided to step down as co-Editor-in-Chief (EIC), of the Journal of Parkinson’s Disease, with immediate effect, following his acceptance of a new position at Roche Pharmaceutical Research and Early Development. As a consequence of his moving away from academia, he now steps down from the journal to prevent any form of conflict of interests.
15 March 2022
The diagnosis of Parkinson’s disease (PD) is currently based on consensus clinical criteria. A novel study in JPD has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau.
30 September 2021
Current knowledge about Parkinson’s disease (PD) does not reflect the diversity of people with the disease, according to The Michael J. Fox Foundation for Parkinson’s Research (MJFF). In a position paper published in JPD, MJFF research staff define four major areas of action to reduce health disparities and advance treatments for everyone with PD. It highlights steps the Foundation is taking in these areas, including a new program launched earlier this year.
23 September 2021
After several decades of pre-clinical development, cell- and gene-based therapies for Parkinson’s disease (PD) are now actively being explored. In this JPD special issue on “Repairing the Parkinsonian Brain,” experts highlight some of the current strategies being pursued to restore lost function and replace what is lost in the PD brain, with special emphasis on the challenges associated with translating advanced therapeutic approaches into pioneering clinical trials.
31 August 2021
Results of a new European study published in JPD may help improve clinical practice by shedding light on the lives of people with PD and their carers, re-emphasizing the many challenges they face in everyday life.
30 August 2021
Patients with Parkinson’s disease (PD) are at higher risk for vaccine-preventable respiratory illnesses. However, patients with advanced PD may have less access to vaccinations according to a new study published in the JPD. More than 30% of patients surveyed did not know whether their physicians
20 July 2021
Amsterdam, NL – Well over six million people globally have been diagnosed with Parkinson’s disease (PD), which has an enormous impact on the lives of patients, their families, and caregivers and is incurring mounting costs for society.